Varlitinib is an inhibitor of EGFR and HER2 (IC50s = 7 and 2 nM, respectively). It inhibits cell proliferation (IC50s = <20 μM) and induces apoptosis in MDA-MB-453 and MDA-MB-468 triple-negative breast cancer (TNBC) cells. Varlitinib inhibits migration, invasion, and mammosphere formation of MDA-MB-231 and MDA-MB-468 cells. In vivo, varlitinib (100 mg/kg) inhibits phosphorylation of EGFR and ERK and reduces tumor weight in an MDA-MB-468 mouse xenograft model.
Varlitinib is an inhibitor of EGFR and HER2 (IC50s = 7 and 2 nM, respectively). It inhibits cell proliferation (IC50s = <20 μM) and induces apoptosis in MDA-MB-453 and MDA-MB-468 triple-negative breast cancer (TNBC) cells. Varlitinib inhibits migration, invasion, and mammosphere formation of MDA-MB-231 and MDA-MB-468 cells. In vivo, varlitinib (100 mg/kg) inhibits phosphorylation of EGFR and ERK and reduces tumor weight in an MDA-MB-468 mouse xenograft model.
Shipping & Handling
Shipped In
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Room Temperature in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.